Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/187152731507160808200737 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Restoring bone healing potential.
Elife
January 2025
Centre for Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Queen Mary University of London, London, United Kingdom.
A combination of intermittent fasting and administering Wnt3a proteins to a bone injury can rejuvenate bone repair in aged mice.
View Article and Find Full Text PDFEvaluating the effectiveness of vaccination campaigns: Insights from unvaccinated mortality data.
Infect Dis Model
March 2025
Mathematical Sciences, School of Science, RMIT University, Melbourne, Australia.
This paper examines a recently developed statistical approach for evaluating the effectiveness of vaccination campaigns in terms of deaths averted. The statistical approach makes predictions by comparing death rates in the vaccinated and unvaccinated populations. The statistical approach is preferred for its simplicity and straightforwardness, especially when compared to the difficulties involved when fitting the many parameters of a dynamic SIRD-type model, which may even be an impossible task.
View Article and Find Full Text PDFCIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma - a short report.
Cancer Drug Resist
December 2024
School of Medicine and Population Health, University of Sheffield, Sheffield S10 2RX, UK.
Circulating tumour cells (CTCs) can be detected in peripheral blood using their physical properties (increased size and less deformable than normal circulating blood cells) or using cell surface markers. The study of these CTCs should provide important insights into tumour biology, including mechanisms of drug resistance. We performed a pilot study (IRAS ID: 235459) to evaluate if CTCs could be isolated from peripheral blood samples collected from soft tissue sarcoma (STS) patients.
View Article and Find Full Text PDFSafety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma.
J Adv Pract Oncol
November 2024
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Follicular lymphoma (FL) is a disease often characterized by chronic and successive relapses after first-line chemoimmunotherapy. Although chemoimmunotherapy and combination therapy, such as lenalidomide with rituximab, are well established in the treatment sequence of FL, there is a need to streamline treatment options and determine placement of novel agents, such as chimeric antigen receptor T-cell therapy, an enhancer of zeste homolog 2 inhibitor, or a phosphoinositide 3 kinase inhibitor, into the treatment landscape. As such, the purpose of this review is to compare the safety profiles of approved agents in subsequent lines of therapy for relapsed or refractory FL and to assess how the management of adverse events may impact treatment choice.
View Article and Find Full Text PDFBackground: This study aimed to determine the status of in-hospital cardiac rehabilitation (CR) and hospital-associated disability (HAD) for patients with acute myocardial infarction (AMI) aged >80 years.
Methods And Results: This study involved the Japanese Registry of All Cardiac and Vascular Diseases and the Diagnosis Procedure Combination databases, and included patients who were hospitalized with AMI from April 2014 to March 2021. Patients were categorized by the daily amount of CR: NA, not applicable; Low, 20-30 min; Moderate, 30-40 min; and High, >40 min.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!